Edition:
India

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

87.49USD
20 Apr 2018
Change (% chg)

$1.21 (+1.40%)
Prev Close
$86.28
Open
$85.93
Day's High
$88.42
Day's Low
$85.93
Volume
48,287
Avg. Vol
86,713
52-wk High
$95.64
52-wk Low
$29.47

Chart for

About

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets:... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $927.79
Shares Outstanding(Mil.): 19.09
Dividend: --
Yield (%): --

Financials

BRIEF-Enanta Pharmaceuticals Reports Q1 Earnings Per Share $0.59

* ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017

08 Feb 2018

BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated

* ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

05 Jan 2018

BRIEF-Enanta Pharma Says Abbvie’s Maviret ‍is Now Commercially Available In Japan​

* ENANTA PHARMACEUTICALS - ABBVIE'S MAVIRET HAS BEEN APPROVED FOR REIMBURSEMENT BY MINISTRY OF HEALTH, LABOUR AND WELFARE

30 Nov 2017

BRIEF-Enanta Pharma Q4 earnings per share $1.86

* Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017

21 Nov 2017

BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist

* Enanta Pharmaceuticals announces positive phase 1 a/b clinical results for its lead fxr agonist, edp-305

23 Oct 2017

Earnings vs. Estimates